medigraphic.com

2014, Number 1

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2014; 15 (1)

Characterization of patients with diabetic foot disease treated with Heberprot-P® in the military hospital of Holguin province

Rodríguez GD

Language: Spanish
References: 16
Page:
PDF size: 139.13 Kb.


ABSTRACT

Introduction: the diabetic foot is considered a global health problem, since it causes a high number of amputations and admissions to hospitals.
Objective: to characterize the patients with this disease treated with Heberprot-P®.
Methods: adescriptive, retrospective, case series study of patients treated with this drug for five months in the angiology and vascular surgery service of the "Fermín Valdez Domínguez" military Hospital in Holguín province.
Results: predominance of male geriatric patients with modifiable risk factors and distal occlusive pattern was observed. There was correspondence between the severity of the injury and the number of Heberprot-P® doses used. Minor non-life-threatening adverse reactions predominated and there was a tendency to perform conservative operations as necrectomies.
Conclusions: the patients with diabetic foot treated with Heberprot-P® had satisfactory progression. This drug proved to be safe and effective and its use is encouraged through the implementation of preventive strategies.


REFERENCES

  1. OPS. La diabetes en las Américas. Boletín Epidemiológico OPS. 2001;22(2):1-3.

  2. Rivero Fernández F, Conde Pérez A, Varela Hernández A, Vejerano García P, Socarrás Olivera N, Otero Reyes M, et al. Resultados de un modelo de atención preventiva del pie diabético en la comunidad. Rev Cubana Angiol y Cir Vasc. 2006 [citado 24 Abr 2009];7(1). Disponible en: http://www. bvs.sld.cu/revistas/ang/vol7_1_06/ang01106.htm

  3. García Herrera AL. Comportamiento de la diabetes mellitus y pronóstico de la lesión neuropática e infecciosa del diabético. Rev Méd Electrón. 2007 [citado 7 Feb 2012];29(5). Disponible en:http://www.revmatanzas.sld.cu/revista%20medica/ano2007/vol5%202007 /tema02.htm

  4. American Diabetes Association 2008. Economic costs of diabetes in the U.S.in 2007. Diabetes Care. 2008;31:596-615.

  5. Garcia-Morales E, Lazaro-Martinez JL, Martinez-Hernandez D, Aragon Sanchez J, Beneit Montesinos JV, Gonzalez-Jurado MA. Impact of diabetic foot related complications on the Health Related Quality of Life (HRQol) of patients, a regional study in Spain. Int J Low Extrem Wounds. 2011;10(1):6-11.

  6. Aragón-Sánchez J, Quintana-Marrero Y, Lázaro-Martínez JL, Hernández-Herrero MJ, García-Morales E, Beneit-Montesinos JV, et al. Necrotizing soft-tissue infections in the feet of patients with diabetes: outcome of surgical treatment and factors associated with limb loss and mortality. Int J Low Extrem Wounds. 2009;8(3):141-6.

  7. Jeffcoate WJ, Lipsky BA, Berendt AR, Cavanagh PR, Bus SA, Peters EJ, et al. Unresolved issues in the management of ulcers of the foot in diabetes. Diabet Med. 2008;25(12):1380-9.

  8. Fernánde Montequín JI, Valenzuela Silva CM, Díaz OG, Savigne W, Sancho Soutelo N, Rivero-Fernández F, et al. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: Multicenter, randomised, placebo-controlled, double-blind study. Int Wound J. 2009;6(6):432-43.

  9. Hernández Rivero MJ, Llanes Barrios JA, Acosta Lapera DS. Heberprot-P, una terapia eficaz en la prevención de la amputación en el pie diabético. Rev Cubana Angiol Cir Vasc. 2009 [citado 15 Jun 2012];10(1):3-11. Disponible en:http://bvs.sld.cu/revistas/ang/vol10_1_09/ang02109.pdf

  10. Fernández Montequin J, Santiesteban L. Experiencias en el uso del Heberprot-P en Venezuela. Reportes de casos del hospital Carlos Arvelo, Caracas. Infiltración del factor de crecimiento epidérmico. Un tratamiento eficaz para la úlcera del pie diabético. La Habana: Editorial Elfos Scientiae; 2009.

  11. Wagner FW. The diabetic foot. Orthopedics. 1987;10(1):163-71.

  12. Malay DS, Margolis DJ, Hoffstad OJ, Bellamy S. The incidence and risks of failure to heal after lower extremity amputation for the treatment of diabetic neuropathic foot ulcer. J Foot Ankle Surg. 2006;45:366-74.

  13. Vejerano P, Rivero F, Travieso R, González L. Morbilidad y mortalidad por pie diabético en nuestro servicio. Rev Cubana Endocrinol. 1990;1(2):142-7.

  14. Clairotte C, Retout S, Potier L, Roussel R, Escoubet B. Automated anklebrachial pressure index measurement by clinical staff for peripheral arterial disease diagnosis in nondiabetic and diabetic patients. Diabetes Care. 2009;32(7):1231-6.

  15. González A, Peña EC, Rodríguez DG. Morbilidad por el síndrome de pie diabético. Rev Cubana Angiol Cir Vasc. 2003 [citado 12 Jun 2012];4(1). Disponible en: http://bvs.sld.cu/revistas/ang/vol4_1_03/ang06103.htm

  16. Franco Pérez N, Valdés Pérez C, Lobaina González R, Inglés Maury N. Comportamiento de la morbilidad y la mortalidad en pacientes con Pie Diabético. Rev Cubana Angiol Cir Vasc. 2001 [citado 14 Jul 20012];2(1). Disponible en:http://bvs.sld.cu/revistas/ang/vol2(1).html




2020     |     www.medigraphic.com